No Data
Hutchmed (China) (00013.HK) has adopted the Long-Term Incentive Plan for 2025.
Gelonghui March 14 news丨Hutchmed (China) (00013.HK) announced that the current long-term incentive plan will expire on April 24, 2025. On March 14, 2025, the Board of Directors approved the adoption of the 2025 Long-Term Incentive Plan. Unless terminated early, the 2025 Long-Term Incentive Plan will be effective from the date of adoption until the tenth anniversary of the adoption date. The 2025 Long-Term Incentive Plan aims to attract and retain skilled and experienced personnel by providing them with the opportunity to acquire company equity, and to motivate them for the future development of the group.
HUTCHMED Announces Vesting of LTIP Awards
HUTCHMED Adopts 2025 Long Term Incentive Plan to Drive Growth
AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.
① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?
Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.
As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.
6-K: Report of foreign private issuer (related to financial reporting)
